Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Time to Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down before the market opened on Monday . The stock had previously closed at $21.87, but opened at $21.10. Chugai Pharmaceutical shares last traded at $20.9540, with a volume of 8,498 shares trading hands.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy”.

Chugai Pharmaceutical Stock Up 2.5%

The firm’s 50 day moving average is $23.25 and its two-hundred day moving average is $26.32. The stock has a market cap of $70.62 billion, a price-to-earnings ratio of 23.32 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. The company had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%. On average, analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.